ClinicalTrials.gg
CompletedNCT03355573BE AGILE 2Updated Nov 21, 2024Results posted

A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis

A Phase 2 interventional study of Bimekizumab in Ankylosing Spondylitis, sponsored by UCB Biopharma SRL. Completed at 50 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-21.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
255
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Spondylitis, Ankylosing by UCB S.A. — none open to participants now, none under way, none of them phase 3. Spondylitis, Ankylosing · UCB S.A..

Started
2017
with 1 other
Phase 2
3 of 11
none open now
Registered
9th of 11
by date

Among the 11 studies in Spondylitis, Ankylosing by UCB S.A., this one is one of 2 that started in 2017, is one of 3 in phase 2, and was the 9th registered.

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

None of the 11 studies in Spondylitis, Ankylosing by UCB S.A. is open now. The open studies under Spondylitis, Ankylosing, anywhere →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Spondylitis, Ankylosing by UCB S.A. as a file.
02

Study summary

This is a study to assess the long term safety and tolerability of bimekizumab in subjects with ankylosing spondylitis

03

Conditions studied

  • Ankylosing Spondylitis

Keywords

  • Bimekizumab
  • Ankylosing Spondylitis
  • AS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In the opinion of the Investigator, the subject is expected to benefit from participation in an Open Label Extension (OLE) study
  • Subject completed AS0008 without meeting any withdrawal criteria
  • Female subjects must be , permanently sterilized or, if of , must be willing to use a highly effective method of
  • Male subjects with a partner of childbearing potential must be willing to use a condom when sexually active

Exclusion criteria

Exclusion Criteria:

  • Female subjects who plan to become pregnant during the study or within 20 weeks following the last dose of medicinal product (IMP). Male subjects who are planning a partner pregnancy during the study or within 20 weeks following the last dose
  • Subjects with any current sign or symptom that may indicate a medically significant active infection (except for the common cold) or has had an infection requiring systemic antibiotics within 2 weeks of study entry
  • Subjects who meet any withdrawal criteria in AS0008. For any subject with an ongoing Serious Adverse Event, or a history of serious infections (including hospitalizations) in the lead-in study, the Medical Monitor must be consulted prior to the subject's entry into AS0009
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
255 participants (actual)

Study arms

  • Experimental
    Bimekizumab

    Subjects will receive bimekizumab up to 4 years.

    Drug: Bimekizumab

Interventions

  • Bimekizumab at a prespecified dose.

    Also known as: UCB4940

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study

    An Adverse Event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Treatment emergent adverse events were defined as those events with onset date on or after the first administration of study medication in AS0009 and on or before 140 days after the final study medication administration.

    Time frame: From Entry Visit (Visit 1) until Safety Follow Up (up to Week 224)

  2. Percentage of Participants With Serious Adverse Event (SAE) During the Study

    A serious adverse event (SAE) is any untoward medical occurrence that at any dose: 1) Results in death 2) Is life-threatening 3) Requires in participant hospitalisation or prolongation of existing hospitalisation 4) Is a congenital anomaly or birth defect 5) Is an infection that requires treatment with parenteral antibiotics 6) Other important medical events which based on medical or scientific judgement may jeopardise the participants, or may require medical or surgical intervention to prevent any of the above.

    Time frame: From Entry Visit (Visit 1) until Safety Follow Up (up to Week 224)

Secondary outcomes

  1. Percentage of Participants Who Withdrew Due to an Treatment-emergent Adverse Event (TEAE) During the Study

    An Adverse Event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Treatment emergent adverse events were defined as those events with onset date on or after the first administration of study medication in AS0009 and on or before 140 days after the final study medication administration.

    Time frame: From Entry Visit (Visit 1) until Safety Follow Up (up to Week 224)

  2. Percentage of Participants With Axial Spondyloarthritis International Society 40% Response Criteria (ASAS40) at Week 48 Calculated Relative to Baseline of AS0008

    The ASAS40 response was defined as relative improvements of at least 40% and absolute improvement of at least 2 units on a 0 to 10 Numeric Rating Scale (NRS), where 0 is "not active" and 10 is "very active" in at least 3 of the 4 domains: Patient's Global Assessment of Disease Activity (PGADA) (score ranged from 0 (not active) to 10 (very active), Pain assessment (total spinal pain NRS score) (assessed on a scale of 0 (no pain) to 10 (severe pain)), Function (Bath Ankylosing Spondylitis Functional Index (BASFI)) (score ranged from 0 (easy) to 10 (impossible)), Inflammation (mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 (none) to 10 (very severe) and no worsening at all in the remaining domain. Participants for whom ASAS could not be derived due to missing data were counted as non-responders.

    Time frame: Baseline of AS0008, Week 48 (AS0009)

  3. Percentage of Participants With Axial Spondyloarthritis International Society 20% Response Criteria (ASAS20) at Week 48 Calculated Relative to Baseline of AS0008

    The ASAS20 response was defined as relative improvements of at least 20% and absolute improvement of at least 1 unit on a 0 to 10 NRS, where 0 is "not active" and 10 is "very active" in at least 3 of the 4 domains: PGADA (score ranged from 0 (not active) to 10 (very active), Pain assessment (total spinal pain NRS score) (assessed on a scale of 0 (no pain) to 10 (severe pain)), Function (BASFI) (score ranged from 0 (easy) to 10 (impossible)), Inflammation (mean of BASDAI) questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 (none) to 10 (very severe) and no worsening at all in the remaining domain. Participants for whom ASAS could not be derived due to missing data were counted as non-responders.

    Time frame: Baseline of AS0008, Week 48 (AS0009)

  4. Change From Baseline of AS0008 in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score to Week 48

    BASDAI is a validated self-reported instrument, which consisted of 6 questions to measure the disease activity of ankylosing spondylitis (AS) from the participant's perspective. It measured the severity of fatigue, spinal and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and duration). Each question was rated using a numerical rating scale from 0 (none) to 10 (very severe), higher score=high disease activity. The BASDAI score was calculated by computing the mean of questions 5 and 6 and adding it to the sum of questions 1 to 4. This score was then divided by 5. The total BASDAI score was ranged from 0=none to 10= very severe, where higher score indicated high disease activity. A negative value indicated improvement and a positive value indicated worsening.

    Time frame: Baseline of AS0008, Week 48 (AS0009)

07

Results

Posted Nov 13, 2024

Participant flow

The study started to enroll study participants in November 2017 and concluded in October 2022. Participants who completed AS0008 (NCT02963506) participated in this study.

Participant flow — Overall Study
MilestoneBimekizumab
Started255
Completed202
Not completed53
Withdrew: Withdrew consent due to refused treatment to ae latent tuberculosis1
Withdrew: Sponsor's decision1
Withdrew: Participant withdrew consent due to aes1
Withdrew: Pi's decision2
Withdrew: Withdrawal by subject23
Withdrew: Lost to follow-up4
Withdrew: Lack of efficacy2
Withdrew: Adverse event, non-fatal17
Withdrew: Adverse event, serious fatal2

Outcome measures

PrimaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study

An Adverse Event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Treatment emergent adverse events were defined as those events with onset date on or after the first administration of study medication in AS0009 and on or before 140 days after the final study medication administration.

Time frame:
From Entry Visit (Visit 1) until Safety Follow Up (up to Week 224)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study
percentage of participantsBimekizumab
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study92.9
PrimaryPercentage of Participants With Serious Adverse Event (SAE) During the Study

A serious adverse event (SAE) is any untoward medical occurrence that at any dose: 1) Results in death 2) Is life-threatening 3) Requires in participant hospitalisation or prolongation of existing hospitalisation 4) Is a congenital anomaly or birth defect 5) Is an infection that requires treatment with parenteral antibiotics 6) Other important medical events which based on medical or scientific judgement may jeopardise the participants, or may require medical or surgical intervention to prevent any of the above.

Time frame:
From Entry Visit (Visit 1) until Safety Follow Up (up to Week 224)
Reported as:
Number · percentage of participants
Percentage of Participants With Serious Adverse Event (SAE) During the Study
percentage of participantsBimekizumab
Percentage of Participants With Serious Adverse Event (SAE) During the Study18.0
SecondaryPercentage of Participants Who Withdrew Due to an Treatment-emergent Adverse Event (TEAE) During the Study

An Adverse Event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Treatment emergent adverse events were defined as those events with onset date on or after the first administration of study medication in AS0009 and on or before 140 days after the final study medication administration.

Time frame:
From Entry Visit (Visit 1) until Safety Follow Up (up to Week 224)
Reported as:
Number · percentage of participants
Percentage of Participants Who Withdrew Due to an Treatment-emergent Adverse Event (TEAE) During the Study
percentage of participantsBimekizumab
Percentage of Participants Who Withdrew Due to an Treatment-emergent Adverse Event (TEAE) During the Study6.7
SecondaryPercentage of Participants With Axial Spondyloarthritis International Society 40% Response Criteria (ASAS40) at Week 48 Calculated Relative to Baseline of AS0008

The ASAS40 response was defined as relative improvements of at least 40% and absolute improvement of at least 2 units on a 0 to 10 Numeric Rating Scale (NRS), where 0 is "not active" and 10 is "very active" in at least 3 of the 4 domains: Patient's Global Assessment of Disease Activity (PGADA) (score ranged from 0 (not active) to 10 (very active), Pain assessment (total spinal pain NRS score) (assessed on a scale of 0 (no pain) to 10 (severe pain)), Function (Bath Ankylosing Spondylitis Functional Index (BASFI)) (score ranged from 0 (easy) to 10 (impossible)), Inflammation (mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 (none) to 10 (very severe) and no worsening at all in the remaining domain. Participants for whom ASAS could not be derived due to missing data were counted as non-responders.

Time frame:
Baseline of AS0008, Week 48 (AS0009)
Reported as:
Number · percentage of participants
Percentage of Participants With Axial Spondyloarthritis International Society 40% Response Criteria (ASAS40) at Week 48 Calculated Relative to Baseline of AS0008
percentage of participantsBimekizumab
Non-responder imputation67.1
Observed case70.5
SecondaryPercentage of Participants With Axial Spondyloarthritis International Society 20% Response Criteria (ASAS20) at Week 48 Calculated Relative to Baseline of AS0008

The ASAS20 response was defined as relative improvements of at least 20% and absolute improvement of at least 1 unit on a 0 to 10 NRS, where 0 is "not active" and 10 is "very active" in at least 3 of the 4 domains: PGADA (score ranged from 0 (not active) to 10 (very active), Pain assessment (total spinal pain NRS score) (assessed on a scale of 0 (no pain) to 10 (severe pain)), Function (BASFI) (score ranged from 0 (easy) to 10 (impossible)), Inflammation (mean of BASDAI) questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 (none) to 10 (very severe) and no worsening at all in the remaining domain. Participants for whom ASAS could not be derived due to missing data were counted as non-responders.

Time frame:
Baseline of AS0008, Week 48 (AS0009)
Reported as:
Number · percentage of participants
Percentage of Participants With Axial Spondyloarthritis International Society 20% Response Criteria (ASAS20) at Week 48 Calculated Relative to Baseline of AS0008
percentage of participantsBimekizumab
Non-responder imputation79.9
Observed case84.0
SecondaryChange From Baseline of AS0008 in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score to Week 48

BASDAI is a validated self-reported instrument, which consisted of 6 questions to measure the disease activity of ankylosing spondylitis (AS) from the participant's perspective. It measured the severity of fatigue, spinal and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and duration). Each question was rated using a numerical rating scale from 0 (none) to 10 (very severe), higher score=high disease activity. The BASDAI score was calculated by computing the mean of questions 5 and 6 and adding it to the sum of questions 1 to 4. This score was then divided by 5. The total BASDAI score was ranged from 0=none to 10= very severe, where higher score indicated high disease activity. A negative value indicated improvement and a positive value indicated worsening.

Time frame:
Baseline of AS0008, Week 48 (AS0009)
Reported as:
Mean · scores on a scale
Change From Baseline of AS0008 in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score to Week 48
scores on a scaleBimekizumab
Change From Baseline of AS0008 in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score to Week 48-3.79 ± 0.13

Adverse events

Collected over From Entry Visit (Visit 1) until Safety Follow Up (up to Week 224). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bimekizumab2/255 (0.8%)46/255 (18%)176/255 (69%)
Most frequent serious events
Showing 10 of 49
Most frequent serious events
EventBimekizumab
PneumoniaInfections and infestations3/255
Corona virus infectionInfections and infestations3/255
Colitis ulcerativeGastrointestinal disorders2/255
Perirectal abscessInfections and infestations2/255
OsteoarthritisMusculoskeletal and connective tissue disorders2/255
Benign prostatic hyperplasiaReproductive system and breast disorders2/255
Coronary artery diseaseCardiac disorders1/255
Coronary artery stenosisCardiac disorders1/255
Cardiac failureCardiac disorders1/255
Cardio-respiratory arrestCardiac disorders1/255
Most frequent other events
Showing 10 of 15
Most frequent other events
EventBimekizumab
NasopharyngitisInfections and infestations46/255
Upper respiratory tract infectionInfections and infestations33/255
Corona virus infectionInfections and infestations30/255
BronchitisInfections and infestations21/255
Alanine aminotransferase increasedInvestigations19/255
PharyngitisInfections and infestations18/255
Oral candidiasisInfections and infestations17/255
HypercholesterolaemiaMetabolism and nutrition disorders16/255
SinusitisInfections and infestations15/255
TonsillitisInfections and infestations15/255

Baseline characteristics

Baseline Characteristics refer to the Safety Set consisted of all participants in the enrolled set who received at least one dose of study medication in AS0009.

Age, Categorical
Age, Categorical(Participants)Bimekizumab
<=18 years0
Between 18 and 65 years245
>=65 years10
Age, Continuous
Age, Continuous(years)Bimekizumab
Mean41.8 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)Bimekizumab
Female38
Male217
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Bimekizumab
White253
Other/Mixed2
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Bimekizumab
Hispanic or Latino1
Not Hispanic or Latino254
08

Study locations

50 sites
  • As0009 30
    Sarasota, Florida 34239, United States
  • AS0009 1
    Duncansville, Pennsylvania 16635, United States
  • AS0009 6
    Dallas, Texas 75231, United States
  • As0009 156
    Dobrich, Bulgaria
  • As0009 151
    Plovdiv, Bulgaria
  • As0009 155
    Plovdiv, Bulgaria
  • As0009 150
    Ruse, Bulgaria
  • As0009 101
    Quebec City, Canada
  • As0009 205
    Brno, Czechia
  • As0009 207
    Olomouc, Czechia
  • As0009 208
    Pardubice, Czechia
  • As0009 210
    Praha 11 Chodov, Czechia
  • As0009 211
    Praha 3, Czechia
  • As0009 201
    Praha 4, Czechia
  • As0009 202
    Praha, Czechia
  • As0009 203
    Zlin, Czechia
  • As0009 304
    Hamburg, Germany
  • As0009 301
    Ratingen, Germany
  • As0009 400
    Budapest, Hungary
  • As0009 403
    Budapest, Hungary
  • As0009 401
    Veszprem, Hungary
  • As0009 466
    Bydgoszcz, Poland
  • As0009 453
    Elblag, Poland
  • As0009 456
    Elblag, Poland
  • As0009 455
    Krakow, Poland
  • As0009 461
    Lublin, Poland
  • As0009 467
    Nowa Sol, Poland
  • As0009 451
    Poznan, Poland
  • As0009 450
    Torun, Poland
  • As0009 454
    Warszawa, Poland
  • As0009 459
    Warszawa, Poland
  • As0009 457
    Wroclaw, Poland
  • As0009 460
    Wroclaw, Poland
  • As0009 465
    Wroclaw, Poland
  • As0009 601
    Moscow, Russian Federation
  • As0009 604
    Moscow, Russian Federation
  • As0009 607
    Moscow, Russian Federation
  • As0009 600
    Saint Petersburg, Russian Federation
  • As0009 606
    Saint Petersburg, Russian Federation
  • As0009 608
    Saint Petersburg, Russian Federation
  • As0009 610
    Saint-petersburg, Russian Federation
  • As0009 801
    A Coruna, Spain
  • As0009 800
    Cordoba, Spain
  • As0009 803
    Santiago de Compostela, Spain
  • As0009 700
    Kyiv, Ukraine
  • As0009 707
    Kyiv, Ukraine
  • As0009 705
    Ternopil, Ukraine
  • As0009 708
    Uzhgorod, Ukraine
  • As0009 706
    Vinnytsia, Ukraine
  • As0009 704
    Zaporizhzhia, Ukraine
09

References and documents

Publications

  • Baraliakos X, Deodhar A, Dougados M, Gensler LS, Molto A, Ramiro S, Kivitz AJ, Poddubnyy D, Oortgiesen M, Vaux T, Fleurinck C, Shepherd-Smith J, de la Loge C, de Peyrecave N, van der Heijde D. Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study. Arthritis Rheumatol. 2022 Dec;74(12):1943-1958. doi: 10.1002/art.42282. Epub 2022 Nov 7. PubMed 35829672 ↗
  • Robinson PC, Machado PM, Haroon N, Gensler LS, Reveille JD, Taieb V, Vaux T, Fleurinck C, Oortgiesen M, de Peyrecave N, Deodhar A. Minimal Impact of the COVID-19 Pandemic on Disease Activity and Health-Related Quality of Life in Patients With Ankylosing Spondylitis Receiving Bimekizumab: Exploratory Analyses From a Phase 2b Open-Label Extension Study. ACR Open Rheumatol. 2022 Sep;4(9):819-824. doi: 10.1002/acr2.11486. Epub 2022 Jul 14. PubMed 35833532 ↗
  • Brown MA, Rudwaleit M, van Gaalen FA, Haroon N, Gensler LS, Fleurinck C, Marten A, Massow U, de Peyrecave N, Vaux T, White K, Deodhar A, van der Horst-Bruinsma I. Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials. Ann Rheum Dis. 2024 Nov 14;83(12):1722-1730. doi: 10.1136/ard-2024-225933. PubMed 38977276 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Oct 2022, 58 months.

Results were first posted in Nov 2024, 2 years after primary completion. A results delay was requested in Oct 2023.

Of 22 phase 2 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 58 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2017
First posted
Nov 28, 2017
StartActual
Nov 28, 2017
Primary completionActual
Oct 19, 2022
CompletionActual
Oct 19, 2022
Results delay requested
Oct 18, 2023
Results first posted
Nov 13, 2024
Last update
Nov 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03355573
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Nov 28, 2017
Start date
Nov 28, 2017
Primary completion
Oct 19, 2022
Completion
Oct 19, 2022
Results posted
Nov 13, 2024
Last update
Nov 21, 2024

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion